BioLife Solutions, Inc. (NASDAQ:BLFS) Receives $29.00 Consensus Price Target from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given an average rating of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $29.00.

Several research firms recently weighed in on BLFS. TD Cowen raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright dropped their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. Benchmark restated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, KeyCorp increased their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th.

BioLife Solutions Trading Down 1.6 %

NASDAQ:BLFS opened at $26.59 on Tuesday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a twelve month low of $14.50 and a twelve month high of $28.88. The business has a 50 day moving average price of $25.28 and a two-hundred day moving average price of $23.91. The company has a market cap of $1.23 billion, a P/E ratio of -25.08 and a beta of 1.91.

Insider Buying and Selling

In other news, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This represents a 2.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 64,259 shares of company stock worth $1,424,708 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Several large investors have recently added to or reduced their stakes in BLFS. Mark Sheptoff Financial Planning LLC purchased a new position in BioLife Solutions during the 3rd quarter worth $28,000. Isthmus Partners LLC grew its position in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter. Quest Partners LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter valued at $57,000. GAMMA Investing LLC lifted its holdings in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of BioLife Solutions during the 2nd quarter valued at $122,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.